References
- CA Naranjo, U Busto, EM Sellers, P Sandor, I Ruiz, EA Roberts, E Janecek, C Domecq, and DJ Greenblatt. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Therap 1981; 30 (2):239–245.
- MEJ Lean. Sibutramine: a review of clinical efficacy. Int J Obes Relat Metab Disord 1997; 21:30–36.
- PJ Leo, JE Hollander, and RD Shih. Phenylpropanolamine and associated myocardial injury. Ann Emerg Med 1996; 28:359–362.
- American Heart Association: Medical Treatment of Obesity. http://www.americanheart.org/presenter.jhtml?identifier=1818. Accessed 9 December 2007.
- NE Flomenbaum, LR Goldfrank, RS Hoffman, MA Howland, NA Lewin, and LS Nelson. Dieting agents and regimens. Toxicologic Emergencies. 8th ed. New York, USA: McGraw-Hill Professional; 2006: 623–624.
- Health Research Group: Protecting Health, Safety and Democracy. http://www.citizen.org/publications/release.cfm?id=7160 Accessed 29 October 2007.
- E Wooltorton. Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias. CMAJ 2002; 166 (10):1307–1308.
- LL Ioannides-Demos, J Proietto, AM Tonkin, and JJ McNeil. Safety of drug therapies used for weight loss and treatment of obesity. Drug Saf 2006; 29 (4):277–302.
- GA Bray, DH Ryan, D Gordon, S Heidingsfelder, F Cerise, and K Wilson. A double-blind randomized placebo-controlled trial of sibutramine. Obes Res 1996; 4:263–270.
- SM Azarisman, YA Magdi, S Noorfaizan, and M Oteh. Myocardial infarction induced by appetite suppressants in Malaysia. NEJM 2007; 357 (18):1873–1874.